Ian Giles

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1875121/ian-giles-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97 papers	2,582 citations	29 h-index	48 g-index
127 ext. papers	3,141 ext. citations	4.7 avg, IF	5.02 L-index

#	Paper	IF	Citations
97	Haemophagocytic lymphohistiocytosis in pregnancy. *Clinical Medicine*, **2021**, 21, e682-e683	1.9	
96	Prescribing anti-rheumatic drugs in pregnancy and breastfeeding-the British Society for Rheumatology guideline scope. *Rheumatology*, **2021**, 60, 3565-3569	3.9	0
95	P065 The road to recovery: developing a new service for urgent face-to-face rheumatology outpatient appointments during the COVID-19 pandemic: a single centre experience. *Rheumatology* , **2021**, 60,	3.9	78
94	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. *Lancet Rheumatology, The*, **2021**, 3, e9-e10	14.2	5
93	A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 1205-1217	5.3	0
92	Identification of a Novel HIF-1-Integrin-NET Axis in Fibrotic Interstitial Lung Disease. *Frontiers in Immunology*, **2020**, 11, 2190	8.4	6
91	A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. *Expert Review of Clinical Immunology*, **2020**, 16, 321-333	5.1	5
90	Mechanisms determining the amelioration of rheumatoid arthritis in pregnancy: A systematic review. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1357-1369	5.3	4
89	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. *Rheumatology*, **2020**, 59, 524-533	3.9	10
88	Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy **2020**, 77-92		0
87	Play attention! Therapeutic aspects to play in delirium prevention and management. *Wellcome Open Research*, **2020**, 5, 277	4.8	
86	A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. *Clinical Medicine*, **2020**, 20, s98	1.9	2
85	P116 A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. *Rheumatology*, **2020**, 59,	3.9	1
84	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. *Lancet Rheumatology, The*, **2020**, 2, e735-e736	14.2	3
83	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. *Blood Reviews*, **2020**, 39, 100610	11.1	42
82	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. *Rheumatology*, **2020**, 59, 146-152	3.9	6
81	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. *Lancet Rheumatology, The*, **2019**, 1, e85-e94	14.2	38

80	Stratifying management of rheumatic disease for pregnancy and breastfeeding. *Nature Reviews Rheumatology*, **2019**, 15, 391-402	8.1	20
79	Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. *Lupus*, **2019**, 28, 893-897	2.6	1
78	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. *RMD Open*, **2019**, 5, e000885	5.9	9
77	Real benefits of ultrasound evaluation of hand and foot synovitis for better characterisation of the disease activity in rheumatoid arthritis. *European Radiology*, **2019**, 29, 6345-6354	8	7
76	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. *Scientific Reports*, **2019**, 9, 1283	4.9	7
75	Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. *Seminars in Arthritis and Rheumatism*, **2019**, 48, 911-920	5.3	35
74	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. *Rheumatology International*, **2019**, 39, 1867-1873	3.6	14
73	Pathogenesis of Antiphospholipid Antibody Syndrome **2019**, 324-337		3
72	Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. *Journal of Rheumatology*, **2019**, 46, 245-250	4.1	41
71	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. *Journal of Autoimmunity*, **2018**, 93, 114-123	15.5	13
70	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. *Swiss Medical Weekly*, **2018**, 148, w14588	3.1	6
69	132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. *Rheumatology*, **2018**, 57,	3.9	1
68	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. *Frontiers in Immunology*, **2018**, 9, 2413	8.4	8
67	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. *Rheumatology Advances in Practice*, **2018**, 2, rky003	1.1	8
66	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. *Frontiers in Immunology* , **2018**, 9, 2244	8.4	8
65	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. *Rheumatology International*, **2017**, 37, 623-631	3.6	10
64	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. *Arthritis and Rheumatology*, **2017**, 69, 1440-1450	9.5	122
63	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity **2017**, 117-143		3

62	Pregnancy Outcomes in Patients with Psoriatic Arthritis. *Journal of Rheumatology*, **2017**, 44, 128-129	4.1	25
61	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. *Arthritis Care and Research*, **2017**, 69, 1714-1723	4.7	12
60	Oxidation of β-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. *PLoS ONE*, **2017**, 12, e0186513	3.7	8
59	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. *Cell Death and Disease*, **2017**, 8, e2549	9.8	13
58	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. *Scientific Reports*, **2017**, 7, 10788	4.9	5
57	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. *Arthritis Research and Therapy*, **2017**, 19, 287	5.7	1
56	Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. *Frontiers in Immunology*, **2017**, 8, 1295	8.4	30
55	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis **2017**, 77-116		3
54	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests **2017**, 171-187		2
53	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. *Rheumatology*, **2016**, 55, 544-52	3.9	7
52	The association between IgG and IgM antibodies against cardiolipin, β-glycoprotein I and Domain I of β-glycoprotein I with disease profile in patients with multiple sclerosis. *Molecular Immunology*, **2016**, 75, 161-7	4.3	12
51	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology*, **2016**, 55, 1693-7	3.9	251
50	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. *Rheumatology*, **2016**, 55, 1698-702	3.9	93
49	Fertility and pregnancy in systemic lupus erythematosus. *Indian Journal of Rheumatology*, **2016**, 11, 128	0.5	6
48	Measuring IgA Anti-β-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. *PLoS ONE*, **2016**, 11, e0156407	3.7	50
47	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. *RMD Open*, **2016**, 2, e000282	5.9	46
46	Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?. *Rheumatology*, **2015**, 54, 655-9	3.9	19
45	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. *Rheumatology*, **2015**, 54, 2042-50	3.9	46

44	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. *Arthritis Research and Therapy*, **2015**, 17, 26	5.7	20
43	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. *Arthritis Research and Therapy*, **2015**, 17, 47	5.7	11
42	Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. *American Journal of Reproductive Immunology*, **2015**, 73, 390-401	3.8	22
41	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. *Rheumatology*, **2015**, 54, 722-7	3.9	49
40	Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. *Autoimmunity Reviews*, **2015**, 14, 153-9	13.6	87
39	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. *BMC Biotechnology*, **2015**, 15, 104	3.5	6
38	Poor adherence to guidelines on early management of acute hot swollen joint(s): an evaluation of clinical practice and implications for training. *International Journal of Clinical Practice*, **2015**, 69, 618-22	2.9	5
37	Antibodies to domain I of β2-glycoprotein I and IgA antiphospholipid antibodies in patients with seronegative antiphospholipid syndrome. *Annals of the Rheumatic Diseases*, **2015**, 74, 317-9	2.4	35
36	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. *PLoS ONE*, **2015**, 10, e0143970	3.7	24
35	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. *Arthritis Research and Therapy*, **2014**, 16, R48	5.7	4
34	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. *Annals of the Rheumatic Diseases*, **2014**, 73, 1362-8	2.4	63
33	Laboratory tests for the antiphospholipid syndrome. *Methods in Molecular Biology*, **2014**, 1134, 221-35	1.4	4
32	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. *Blood*, **2014**, 124, 3808-16	2.2	14
31	Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results. *Arthritis Care and Research*, **2014**, 66, 757-64	4.7	40
30	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. *Thrombosis and Haemostasis*, **2013**, 109, 72-8	7	16
29	Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review. *Seminars in Arthritis and Rheumatism*, **2012**, 41, 720-36	5.3	25
28	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. *Rheumatology*, **2012**, 51, 1877-80	3.9	22
27	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. *Annals of the Rheumatic Diseases*, **2012**, 71, 1973-9	2.4	46

26	Wrist joint aspiration. *British Journal of Hospital Medicine (London, England: 2005)*, **2012**, 73, C2-4	0.8	
25	Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. *American Journal of Reproductive Immunology*, **2011**, 66, 286-96	3.8	58
24	Evaluating the conformation of recombinant domain I of (2)-glycoprotein I and its interaction with human monoclonal antibodies. *Molecular Immunology*, **2011**, 49, 56-63	4.3	14
23	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. *Arthritis and Rheumatism*, **2011**, 63, 3512-21		11
22	United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. *Rheumatology*, **2011**, 50, 32-9	3.9	52
21	The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. *Lupus*, **2011**, 20, 5-13	2.6	57
20	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. *Rheumatology*, **2011**, 50, 1401-8	3.9	67
19	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. *Journal of Experimental Medicine*, **2010**, 207, 763-76	16.6	48
18	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. *Journal of Immunology*, **2010**, 184, 6622-8	5.3	58
17	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. *Rheumatology*, **2010**, 49, 392-4	3.9	39
16	Use of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies. *Lupus*, **2010**, 19, 359-64	2.6	2
15	Antibodies to serine proteases in the antiphospholipid syndrome. *Current Rheumatology Reports*, **2010**, 12, 45-52	4.9	24
14	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. *Arthritis and Rheumatism*, **2010**, 62, 845-54		88
13	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. *Journal of Immunology*, **2009**, 182, 4836-43	5.3	18
12	Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?. *Lupus*, **2009**, 18, 671-5	2.6	20
11	How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. *Best Practice and Research in Clinical Rheumatology*, **2009**, 23, 525-37	5.3	7
10	Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. *American Journal of Reproductive Immunology*, **2009**, 62, 96-111	3.8	133
9	Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?. *Current Rheumatology Reviews*, **2009**, 5, 83-97	1.6	4

8	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. *Current Rheumatology Reviews*, **2008**, 4, 2-11	1.6	2
7	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. *Arthritis and Rheumatism*, **2007**, 56, 280-90		115
6	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. *Arthritis and Rheumatism*, **2007**, 56, 2392-401		11
5	Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. *Journal of Immunology*, **2006**, 177, 1729-36	5.3	27
4	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. *BMC Biotechnology*, **2006**, 6, 8	3.5	30
3	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. *Arthritis Research*, **2005**, 7, R47-56		17
2	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. *Molecular Immunology*, **2004**, 40, 745-58	4.3	15
1	A career in rheumatology. *BMJ, The*, **2003**, 326, S157	5.9	